Bristol-Meyers Squibb Launches New Lung Cancer Treatment in UK

Friday, August 7, 2015

Source: PMLiVE

Bristol-Myers Squibb has launched its PD-1 inhibitor Opdivo (nivolumab) in the UK as a second-line therapy for squamous non-small cell lung cancer (NSCLC) after chemotherapy.

View All News »